Heart rate decrease during crizotinib treatment and potential correlation to clinical response.
about
Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategyCrizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer.Factors associated with sinus bradycardia during crizotinib treatment: a retrospective analysis of two large-scale multinational trials (PROFILE 1005 and 1007).A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology.Managing treatment-related adverse events associated with Alk inhibitorsCurrent status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer.ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?The efficacy of crizotinib in patients with ALK-positive nonsmall cell lung cancer.Crizotinib-induced cardiotoxicity: the importance of a proactive monitoring and management.Effect of alectinib on cardiac electrophysiology: results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studies.Anaplastic lymphoma kinase-positive lung adenocarcinoma patient with development of sick sinus syndrome while on targeted treatment with crizotinib.Atrial fibrillation was changed into sinus bradycardia in a ROS1-positive advanced lung adenocarcinoma patient who achieved durable response to Crizotinib: A case report and literature review.Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review.Targeted sequencing reveals genetic variants associated with sensitivity of 79 human cancer xenografts to anticancer drugs.Lung cancer as a cardiotoxic state: a review.Crizotinib Inhibits Hyperpolarization-activated Cyclic Nucleotide-Gated Channel 4 Activity.When crizotinib-induced bradycardia becomes symptomatic: role of concomitant drugs.
P2860
Q26795555-876A087A-E793-4F18-8009-D17FDD943804Q34388696-1281AA88-F98E-47E9-9200-9784AA57EB88Q36797256-42357FB9-6997-4B90-BA7A-FC9A178B88A0Q37052843-719988B2-5F34-4C25-B39E-62A7BAFF8B00Q37577639-6AE56750-790B-421E-BFA7-D33D4C718019Q38148969-C9FE1E8D-F034-4C14-8403-C0FABCE55144Q38270016-345C6DC4-6357-4F23-B7D0-349F635CD2E5Q38388307-7B139F4F-72E3-424B-9CCC-2F3262318C98Q38551764-D6F03226-E43A-410C-9E16-4B10C652CD8CQ38938203-A96E3A43-6859-4A82-B333-3FC92D4AC516Q39308996-D153F49D-EE2E-4F89-A7C2-B9FC1EA5F28CQ39326635-8E2B3923-C5FA-4112-AFD7-F24F8977FDC2Q49244147-E1930954-4C33-409E-B739-2D70BC95E065Q49446395-9B73DFAE-5BDC-42BF-AF61-CCFFCA5DD06FQ53117997-68DD8ED9-DAEC-4F8F-B4C1-71C48CBF3C78Q55004308-746F3384-BC35-4E7B-BD04-EAE68093D735Q55059446-71281001-9FB8-484A-8FDB-62B013C6DEB0
P2860
Heart rate decrease during crizotinib treatment and potential correlation to clinical response.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Heart rate decrease during cri ...... relation to clinical response.
@en
type
label
Heart rate decrease during cri ...... relation to clinical response.
@en
prefLabel
Heart rate decrease during cri ...... relation to clinical response.
@en
P2093
P2860
P356
P1433
P1476
Heart rate decrease during cri ...... relation to clinical response.
@en
P2093
Christina Siwak-Tapp
Jonathan A Stiber
Michele Azada
Wilson P Tong
P2860
P304
P356
10.1002/CNCR.28040
P407
P577
2013-03-15T00:00:00Z